WO2020071630A1 - Composition pour améliorer la peau comprenant des extraits de produits naturels - Google Patents

Composition pour améliorer la peau comprenant des extraits de produits naturels

Info

Publication number
WO2020071630A1
WO2020071630A1 PCT/KR2019/009888 KR2019009888W WO2020071630A1 WO 2020071630 A1 WO2020071630 A1 WO 2020071630A1 KR 2019009888 W KR2019009888 W KR 2019009888W WO 2020071630 A1 WO2020071630 A1 WO 2020071630A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
ppm
present
cosmetic composition
Prior art date
Application number
PCT/KR2019/009888
Other languages
English (en)
Korean (ko)
Inventor
김지형
김정은
이소영
진무현
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Publication of WO2020071630A1 publication Critical patent/WO2020071630A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention relates to a cosmetic composition, a food composition or a quasi-drug composition comprising as an active ingredient a glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or kawa extract.
  • ⁇ for anti-oxidation, including molybdenum, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract as an active ingredient; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it relates to a composition for skin regeneration.
  • Skin is increasingly damaged by age or by ultraviolet, external contaminants and stress, and the ability to protect the skin from these factors is weakened, resulting in poor cell protection and proliferation.
  • the body begins the process of skin rejuvenation against damaged skin.
  • Skin regeneration is the tissue's response to damage and is the process of tissue recovery, which lasts from 2 days to 3 weeks after the skin is damaged.
  • fibroblasts accumulate collagen to fill the blemishes of damaged skin, induce proliferation of fibroblasts, and reconstruction of new cells and interstitial components in the wound site.
  • the concentration of free radicals in the body is increased, and these free radicals attack the cellular components of lipids, proteins, sugars, and DNA, thereby causing a peroxidation reaction, thereby promoting skin aging. Accordingly, there is a need to develop a cosmetic composition having an antioxidant effect that inhibits the generation of free radicals and an anti-aging (anti-aging) effect.
  • Human skin color is determined by a number of factors, including the activity of melanocytes, the distribution of blood vessels, the thickness of the skin, and the presence or absence of pigments inside and outside the human body.
  • enzymes such as tyrosinase in melanocytes
  • the black pigment called melanin produced by action is important.
  • Melanin is present in the skin and plays an important function of protecting the body from ultraviolet rays, but when over-produced, it is known to promote pigmentation and skin aging and play a major role in inducing skin cancer.
  • cosmetics are used to protect the skin, and various ingredients such as surfactants, preservatives, fragrances, sunscreens, and pigments are known to cause various problems such as inflammation, rash, and edema on the skin (Maibach. HI, Contact Dermatitis) , 6. 369-404, 1980).
  • skin inflammation is caused by ultraviolet rays from the sun, and skin, as the sebum, sweat, fatty acids, and proteins in the cosmetic components discharged from the body are decomposed into highly toxic substances by the skin bacterial flora present on the skin. Inflammation may also be caused.
  • Inflammatory reaction is a physiological reaction to protect the living body from the invasion and mechanical damage of foreign substances such as bacteria, and causes phenomena such as redness, tingling, burning, swelling, and tissue changes. It can also cause harmful damage to the fields. Therefore, if the inflammation-inducing factor is not eliminated, chronic inflammation occurs as a result, resulting in even more serious tissue damage. Accordingly, there is an urgent need to develop a cosmetic composition capable of initially suppressing skin troubles through anti-inflammatory effects.
  • Collagen is a major matrix protein produced in fibroblasts of the skin, and maintains the mechanical firmness of the skin and the cohesion of tissues, supports cell adhesion, and induces cell differentiation. Collagen decreases with age and photoaging by ultraviolet irradiation, and collagen reduction is accelerated by collagenase enzyme activity that breaks down collagen. This is known to be closely related to the formation of wrinkles on the skin.
  • elastin occupies a relatively small portion of the fiber components in the dermis, and is known to have elasticity on skin, lungs, and blood vessels, and elastic fibrous gastric yellow tumor (PXE: pseudoxanthoma elasticum) due to atrophy of elastin. It is known that skin elasticity decreases when this occurs.
  • PXE pseudoxanthoma elasticum
  • Retinol is a substance that promotes collagen synthesis and inhibits the elastase enzyme, but is unstable and has limited use due to safety problems such as irritation and rash when applied to the skin. Is said to be difficult.
  • glycation a non-enzymatic reaction in which a simple sugar such as glucose or fructose forms a covalent bond occurs in the protein or fat of the protein in the body, and this is called glycation.
  • Glycosylated collagen prevents collagen from forming an appropriate structure in the extracellular matrix of the dermal layer, thereby losing skin elasticity and promoting wrinkle formation.
  • advanced glycation end products (AGEs) produced by saccharification are brownish substances that accumulate on the top of the dermal layer as the skin ages and the reflected light reflected from the skin decreases. Accordingly, the final glycation end product increases as the skin aging progresses, and is gradually regarded as one of the substances that make the face yellow and gray (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). .
  • Aminoguanidine, Pyridoxamine, Aspirin, etc. are known as substances that inhibit glycation, but these substances have practical limitations due to limitations in use or insignificant effects due to safety problems with the skin. There is a problem that can not be expected.
  • the present inventors conducted research on substances having excellent antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity improvement, and skin regeneration effect among natural resources, and 7 kinds of natural materials extracts
  • the present invention was completed by confirming anti-glycosylation, melanin reduction, collagen synthesis promotion, elastase activity inhibition, and cell proliferation effect.
  • An object of the present invention is to provide a cosmetic composition comprising as an active ingredient, glutinous, bovine, rhubarb, Osuyu, Ohpilcho, Hyangchunja or Kawa extract.
  • antioxidant for containing the extract as an active ingredient For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or to provide a composition for skin regeneration.
  • Another object of the present invention is to provide a food composition
  • a food composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
  • Still another object of the present invention is to provide a quasi-drug composition
  • a quasi-drug composition comprising as an active ingredient a glutinous, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extract.
  • the composition of the present invention has excellent anti-glycosylation, melanin reduction, anti-inflammatory, collagen synthesis promotion, elastase activity inhibition, cell proliferation effect, antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement, It can be usefully used for skin regeneration. Therefore, the composition of the present invention can be used as a cosmetic composition, a food composition, and a quasi-drug composition that is safe for skin and has an excellent skin condition improving effect.
  • One aspect of the present invention provides a cosmetic composition
  • a cosmetic composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
  • Cynops gallae-tinctoria is a worm hump produced by the spawning of vulgaris on young branches of a beech family, the outer surface of which is brown or olive green with small projections and the quality is solid. It contains tangible asset-based tannins, and is mainly used for dyes, leather tans, hair dyes, and ink materials.
  • caesalpinia sappan is a legume and evergreen tree distributed in tropical Asia, such as India, Malaysia, and southern China, and is also called firewood, red-eye, crimson, and the like.
  • the red-yellow wood part is used as a red dye
  • the root is used as a yellow dye.
  • it may mean a medicine using the heartwood of the tree, which has been mainly used for prescription of antibacterial, anti-inflammatory, and analgesic drugs in oriental medicine.
  • Rhuum Rheum officinale
  • Nodaceae a perennial plant belonging to the family Nodaceae, which is distributed around the world and grows in valley wetlands. It has thick yellow roots, rough stems, hollow, straight stems up to 1 m high. Specifically, it may mean a medicine made using rhizomes of Rheum officinale Baillon , which has been mainly used for treatment of constipation, nosebleeds, diuresis, and edema in oriental medicine.
  • Esudia Evodia rutaecarpa
  • Esudia Evodia rutaecarpa
  • oleaceae tree which is an herbaceous plant, warms the stomach, relieves pain, and regulates circulation of the vomiting, headache, stomatitis, toothache, etc. It has been mainly used for treatment.
  • Optilla gariana potentilla gariana
  • Garaknamul a perennial plant that extends in all directions, lying on the ground
  • Saham a perennial plant that extends in all directions, lying on the ground
  • Weft a perennial plant that extends in all directions, lying on the ground
  • Fine hairs are lying at an angle on the whole body, and several stems split at the base grow to a height of about 50cm. It has antipyretic, antitussive, detoxifying, and edema effects, so it has been used as a medicine for antipyretic, cough, and sore throat in oriental medicine.
  • Haangchunja Toona sinensis .
  • oriental medicine it has been used for the treatment of colds and rheumatoid arthritis.
  • Kawa Piper methysticum , kava
  • kava a black pepper shrub found in Polynesia, Melanesia, and Micronesia, such as Awa (Hawaii), Ava (Samoa), Yagona (Fiji), Sakau (Ponpei).
  • Hamahama or Kaaba Kaba Specifically, it may mean a root region, and it is known that the carabalactone extracted from the root region has a sedative, sleep-inducing, and anesthetic effect.
  • extract is an extract obtained by the extraction treatment of molybdenum, bovine, rhubarb, sorghum, opilcho, hyangchunja or kawa, dilution or concentrate of the extract, dried product obtained by drying the extract, the extract And extracts of all formulations that can be formed using the extract itself and the extract, such as a crude or purified product, or mixtures thereof.
  • the extract may be extracted from natural, hybrid, or varietal plants of molluscs, cedar, rhubarb, oleander, opilcho, hyangchunja, or kawaii, and can also be extracted from plant tissue cultures.
  • the method of extracting the extract of molybdenum, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa is not particularly limited, and may be extracted according to a method commonly used in the art. Hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, these may be performed alone or in combination of two or more methods, but are not limited thereto.
  • the type of the extraction solvent used for extraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • the extraction solvent includes water (or distilled water); Lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; And hydrocarbon-based solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture of these may be used, but is not limited thereto.
  • a solvent extract may be prepared by extracting one or more times using the solvent, and a dry extract obtained by distilling the solvent extract under reduced pressure and then freeze-drying or spray drying may be prepared.
  • methanol was used to prepare a molar, bovine, rhubarb, osuyu, opilcho, hyangchunja, and kawaii extract, and then confirm its skin improvement efficacy.
  • the mole meal, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extract may be included in the form of fractions thereof, processed products thereof, animals and plants containing them, and extracts thereof.
  • fraction means a result obtained by performing fractionation to separate a specific component or a specific component group from a mixture comprising various various constituents.
  • the fractionation method for obtaining a fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • Non-limiting examples of the fractionation method include, but are not limited to, a method of obtaining a fraction from the extract by treating a predetermined solvent to an extract obtained by extracting molybdenum, cedar, rhubarb, osuyu, opilcho, hyangchunja, or kawa Does not.
  • the type of solvent used in the fraction is not particularly limited, and any solvent known in the art may be used.
  • the fractional solvent includes polar solvents such as water and alcohol; Non-polar solvents such as Hexane, Ethyl acetate, Chloroform, and Dichloromethane may be used, and these may be used alone or in combination of two or more, but are not limited thereto.
  • the cosmetic composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
  • antioxidation means inhibiting cell oxidation by free radicals or reactive oxygen species, which are highly reactive according to oxidative stress due to the effects of metabolism or ultraviolet rays in cells. And removing free radicals or free radicals, thereby reducing cell damage.
  • skin moisturizing means to increase the feeling of moisture on the skin and maintain a moist state. Increasing the skin moisturizing effect can have a beneficial effect on improving the wrinkles and increasing the elasticity of the skin.
  • skin whitening refers to lightening the skin tone by inhibiting the synthesis of melanin pigments and improving skin hyperpigmentation, such as ultraviolet rays, hormones or oil-induced freckles and freckles. This whitening effect can be achieved, for example, by reducing the total amount of melanin pigment, but the present invention is not limited to this mechanism of action.
  • improve skin trouble refers to inhibiting or inhibiting the generation of troubles on the skin, or alleviating the problems that have already been created, and can be achieved by anti-inflammatory, but the present invention is based on this mechanism of action. It is not limited.
  • the skin trouble refers to a skin disease that may be caused by inflammation caused by excessive nitrogen monoxide production in macrophages. If it is a skin disease related to inflammation, it is included regardless of its type, and the skin disease related to inflammation includes atopic dermatitis, psoriasis, radiation, chemicals, burns, erythematous diseases, acid burns, blistering skin diseases, and thyroid patterns Types of diseases, including itching due to allergies, seborrheic eczema, rose acne, vulgar erythema, polymorphic exudative erythema, nodular erythema, inflammatory hair loss such as glansitis, vulvitis, alopecia areata, skin T-cell lymphoma, etc. , Skin rash, acne, rash, injection (red nose), but is not limited thereto.
  • the anti-inflammatory means inhibiting the inflammation developed in the skin, which can be achieved by inhibiting excessive nitric oxide (NO) production.
  • the composition of the present invention may have an effect of improving skin trouble such as acne through the anti-inflammatory effect.
  • wrinkle improvement refers to suppressing or inhibiting the formation of wrinkles on the skin, or to relieve wrinkles already created.
  • enhancing skin elasticity means to relieve the degree of sagging or sagging skin.
  • skin regeneration means that the skin tissue is restored against damage caused by external and internal causes of the skin.
  • the damage caused by the external cause may include ultraviolet rays, external pollutants, wounds, trauma, etc., and the damage caused by the internal cause may include stress, but is not limited thereto.
  • the composition of the present invention may have anti-glycosylation, melanin reduction, anti-inflammatory, collagen synthesis promotion, elastase activity inhibition, cell proliferation effect.
  • anti-oxidant and anti-glycosylation effects melanin production inhibitory effect, NO production inhibitory effect, type 1 collagen, type 1 collagen Synthetic promoting effect, elastase activity inhibitory effect, cell proliferation effect (Table 1 to Table 7), antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration use It was confirmed that it can be used.
  • the cosmetic composition of the present invention is a solution, external ointment, cream, foam, nutrient makeup, softening makeup, pack, softening water, makeup base, essence, liquid cleaning agent, bathing agent, sunscreen cream, sun oil, suspension, emulsion, paste, Gels, lotions, powders, soaps, surfactant-containing cleansing agents, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays can be prepared in a formulation selected from the group consisting of, but are not limited to.
  • the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and for example, oils, water, surfactants, moisturizers, lower alcohols as common ingredients, Thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately blended, but are not limited thereto.
  • the cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
  • the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these may be used, but are not limited thereto.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, especially in the case of a spray, additional chloro Propellants such as fluorohydrocarbon, propane / butane or dimethyl ether, but are not limited thereto.
  • a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-Butylglycol oil can be used, in particular cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. However, it is not limited thereto.
  • liquid diluents such as water, ethanol or propylene glycol as carrier components
  • suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. may be used, but are not limited thereto.
  • the formulation of the present invention is a soap
  • alkali metal salts of fatty acids fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc.
  • carrier components such as soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc.
  • Another aspect of the present invention provides a food composition
  • a food composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
  • the food composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
  • the food composition may be used in the form of a health functional food, but is not limited thereto.
  • the food composition of the present invention may include food additives, food additives, in addition to edible, bovine, rhubarb, miso, pilcho, hyangchunja or kawa extract.
  • food supplement additive means a component that can be supplementally added to food, and is added to prepare a health functional food of each formulation, and can be appropriately selected and used by a person skilled in the art.
  • food additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like.
  • the food composition of the present invention may include a health functional food.
  • the healthy food refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using ingredients or ingredients having useful functionality for the human body.
  • the term "functionality" means obtaining a useful effect for health use, such as adjusting nutrients or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be manufactured by a method conventionally used in the art, and may be prepared by adding raw materials and ingredients commonly added in the art.
  • the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food.
  • the food composition of the present invention can be manufactured in various types of formulations, and has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material, unlike general medicines, and is excellent in portability.
  • Health functional foods can be consumed as supplements for antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement or skin regeneration effect.
  • the health functional food of the present invention can take, it may include all foods in a common sense, and it is interchangeable with terms known in the art, such as functional food.
  • the health functional food of the present invention can be prepared by mixing appropriate other auxiliary ingredients and known additives that may be included in the food according to the choice of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, various soups, beverages, teas, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding the extract according to the present invention as a main component, and adding it to juice, tea, jelly, and juice. It also includes foods used as feed for animals.
  • Another aspect of the present invention provides a quasi-drug composition
  • a quasi-drug composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, opilcho, hyangchunja or Kawa extract.
  • the quasi-drug composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
  • the quasi-drug composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents, if necessary, in addition to edible, bovine, rhubarb, miso, filcho, or kawa extract.
  • the pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, for example, fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. It can contain.
  • Representative examples of pharmaceutically acceptable carriers, excipients or diluents of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , Injectable ester, witepsol, macrogol, tween 61, cacao butter, laurid, and the like, but is not limited thereto.
  • the quasi-drug composition of the present invention may be exemplified by disinfecting cleansers, shower foams, ointments, wipes, coatings, etc., but is not limited thereto, and formulation methods, dosages, methods of use, and components of quasi-drugs are generally known in the art. It can be appropriately selected from the technology.
  • the cosmetic composition, food composition, and quasi-drug composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions.
  • it may include antioxidants, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration ingredients known in the art. Due to the additional ingredients, the antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration effect of the composition of the present invention may be further enhanced.
  • the content range of additional ingredients may be appropriately adjusted by a person skilled in the art in consideration of skin safety according to the combined use, ease of formulation, and stability of active ingredients.
  • the present invention comprises the step of applying a mosquito, bovine, rhubarb, Osu, Opilcho, Hyangchunja or Kawa extract to the skin of an individual, antioxidant; Skin moisturizing; Skin whitening; Skin trouble improvement; wrinkle improvement; Promoting skin elasticity; Or provide a method for skin regeneration.
  • the individual may include, without limitation, mammals including rats, livestock, and humans.
  • the dry meal was put in a flask 100 g of dry weight and extracted at 70 ° C. for 3 hours with 3000 g of extraction solvent (70% MeOH).
  • the extract was filtered through a filter having a pore size of 0.2 ⁇ m, concentrated, and dissolved in distilled water at 1:10 to prepare a molar extract.
  • Hyangchunja extract After drying and slicing Hyangchunja well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C for 3 hours. The extract was filtered through a filter having a pore size of 0.2 ⁇ m, concentrated, and dissolved in distilled water at 1:10 to prepare a Hyangchunja extract.
  • 1,1-diphenyl-2-picrylhydrazyl (1,1-diphenyl-2-picrylhydrazyl; DPPH) method to measure the free radical scavenging ability (Blois, Nature 181, 1190, 1958).
  • DPPH is a relatively stable free radical that exhibits maximum absorption at 517 nm when present in a radical state and loses absorbance when the radical is eliminated.
  • DPPH was used by Sigma, and dissolved in methanol at a concentration of 0.15 mM.
  • Vitamin C an extract or a positive control
  • 100 ⁇ l of DPPH solution was added thereto. After standing at room temperature for 30 minutes, the absorbance at 517 nm was measured using a microplate reader (BioTek EL-340).
  • the concentration of the extract (IC 50 ) when the absorbance of the sample treated is half the absorbance of the control group is summarized in Table 1 below. The experiment was performed three times, and the average value was calculated and presented.
  • 1M L-arginine and 1M glucose were dissolved in 1M phosphate buffer solution (pH 7.4), and samples were prepared by diluting the sample to 25-50 ppm using 1M phosphate buffer solution.
  • 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1: 4, and then 80 ⁇ l was dispensed in a 96-well plate.
  • 100 ⁇ l of samples diluted with 25 to 50 ppm each and 0.01 M aminoguanidin to be used as a positive control were added.
  • glucose diluted with 1 M phosphate buffer solution was added so that the final concentration of glucose was 0.1 M, followed by reaction at 70 ° C. for 4 hours.
  • the 96-well plate was measured for absorbance by measuring the absorbance at 420 nm using a spectrophotometer.
  • Glycation experimental group of the following formula is an experimental group inducing saccharification by adding 1M L-arginine and 1M glucose, and in order to measure the absorbance of the sample itself, absorbance was measured at 420 nm by adding only 1M L-arginine and a sample without adding glucose.
  • the glycation inhibition rate (%) was calculated using the following formula, and after performing the experiment three times, the average value was calculated and summarized in Table 2.
  • Example 1 (50 ppm) 63.14 Example 1 (25 ppm) 36.31 Example 2 (50 ppm) 48.72 Example 2 (25 ppm) 29.76 Example 3 (50 ppm) 51.92 Example 3 (25 ppm) 39.82 Example 4 (50 ppm) 59.78 Example 4 (25 ppm) 41.70 Example 5 (50 ppm) 47.03 Example 5 (25 ppm) 27.63 Example 6 (50 ppm) 58.47 Example 6 (25 ppm) 36.92 Example 7 (50 ppm) 60.86 Example 7 (25 ppm) 38.57
  • the whitening effect is obtained by measuring the total amount of melanin by adding the extract to a culture medium of mouse melanoma cells (B-16 mouse melanoma cells).
  • B-16 mouse melanoma cells was confirmed.
  • the whitening evaluation was performed by selecting the non-toxic concentration by evaluating the toxicity of the melanoma cells of the mouse.
  • DMSO was used as a negative control
  • albutin was used as a positive control.
  • the sample was added to the medium so that the final concentration was 1 to 10 ppm, and arbutin was added to the medium to be 100 ppm, and then melanoma cells were cultured for 3 days. Thereafter, cells were trypsin-treated, separated from the culture vessel, centrifuged, and melanin was extracted. 1 ml of sodium hydroxide solution (1N concentration) was added to the detached cells and boiled for 10 minutes to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.
  • the amount of melanin was measured by a method represented by absorbance per unit cell number (1 ⁇ 10 6 cells).
  • the total amount of melanin relative to the control group was calculated as the rate of inhibition of melanin production (%), and the average value was calculated after performing the experiment three times and summarized in Table 3.
  • Example 1 (10 ppm) 0.241 26.97
  • Example 1 (1 ppm) 0.273 17.27
  • Example 2 (10 ppm) 0.248 24.85
  • Example 2 (1 ppm) 0.294 10.91
  • Example 3 (10 ppm) 0.257 22.12
  • Example 3 (1 ppm) 0.294 10.91
  • Example 4 (10 ppm) 0.261 20.91
  • Example 4 (1 ppm) 0.284 13.94
  • Example 5 (10 ppm) 0.259 21.52
  • Example 5 (1 ppm) 0.291 11.82
  • Example 6 (10 ppm) 0.239 27.58
  • Example 6 (1 ppm) 0.283 14.24
  • Example 7 (10 ppm) 0.252 23.64
  • Example 7 (1 ppm) 0.281 14.85
  • nitric oxide (NO) production was measured by the GRIESS method using the RAW264.7 cell line (ATCC number: CRL-2278).
  • RAW264.7 cells which are macrophages of mice, were passaged several times, 3 ⁇ 10 5 cells per well were placed in a 24-well plate, and cultured for 24 hours. Subsequently, it was replaced with a cell medium containing a sample at a concentration of 1 to 100 ppm.
  • L-NG-monomethylarginine (L-NMMA) an inhibitor of NO production
  • LPS Lipopolysaccharide
  • the inhibition rate of NO production (%) was calculated using the following formula, and the average value was calculated after performing the experiment three times and summarized in Table 4.
  • Example 1 (1 ppm) 11.24 Example 1 (10 ppm) 18.30 Example 1 (100 ppm) 32.51 Example 2 (1 ppm) 1.54 Example 2 (10 ppm) 12.85 Example 2 (100 ppm) 22.29 Example 3 (1 ppm) 19.38 Example 3 (10 ppm) 20.37 Example 3 (100 ppm) 34.09 Example 4 (1 ppm) 16.30 Example 4 (10 ppm) 17.29 Example 4 (100 ppm) 23.51 Example 5 (1 ppm) 9.73 Example 5 (10 ppm) 18.51 Example 5 (100 ppm) 33.91 Example 6 (1 ppm) 16.88 Example 6 (10 ppm) 19.21 Example 6 (100 ppm) 21.48 Example 7 (1 ppm) 11.84 Example 7 (10 ppm) 19.50 Example 7 (100 ppm) 21.30
  • the extracts of Examples 1 to 7 were added to the culture medium of human-derived fibroblasts to confirm the effect of promoting collagen type 1 synthesis at the cellular level.
  • the measured collagen was quantified using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay KIT).
  • PICP EIA kit Procollagen Type I C-Peptide Enzyme Immuno Assay KIT.
  • DMEM medium culture medium
  • the degree of collagen synthesis was measured at 450 nm using a spectrophotometer.
  • the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium (negative control) and vitamin C (positive control) of untreated fibroblasts were added to a final concentration of 52.85 ⁇ g / ml.
  • the increase rate of collagen production (%) was calculated as the ratio of the amount of collagen production relative to the negative control group. The average value was calculated after performing the experiment three times and summarized in Table 5.
  • Example 1 (1 ppm) 172.8 15.1
  • Example 1 (10 ppm) 231.7 54.3
  • Example 2 (1 ppm) 191.2 27.3
  • Example 2 (10 ppm) 223.3 48.7
  • Example 3 (1 ppm) 181.2 20.6
  • Example 3 (10 ppm) 243.6 62.18
  • Example 4 (1 ppm) 179.1 19.2
  • Example 4 (10 ppm) 223.7 48.9
  • Example 5 (1 ppm) 201.1 33.9
  • Example 5 (10 ppm) 254,9 69.7
  • Example 6 (1 ppm) 192.7 28.3
  • Example 6 (10 ppm) 257.5 71.4
  • Example 7 (1 ppm) 178.4 18.8
  • Example 7 (10 ppm) 229.4 52.7
  • Elastase an enzyme that breaks down Elastin
  • Elastase Elastase derived from human leukocyte cells was used, and a synthetic substrate, MeOSuc-Ala-Ala-Pro-Val-pNA, was used.
  • a buffer solution of 100 mM Tris (pH 7.5) was used.
  • Elastase was finally used 0.2 mU using a buffer solution.
  • the synthetic substrate of elastase was diluted with a buffer solution to make a final concentration of 0.5mM after preparing a 100mM solution using DMSO.
  • the positive control group was set to contain 10 ppm of quercetin, known as an elastase inhibitor.
  • Elastase inhibition candidates were added so that the final concentration was 10 to 20 ppm. The reaction was carried out in a 96-well plate and reacted at room temperature for 20 minutes.
  • the absorbance was measured at 405 nm at 1 minute intervals using a spectrophotometer, and the slope of the absorbance versus time was determined to determine the activity of the enzyme.
  • the elastase inhibition rate (%) was calculated using the following formula, and the average value was calculated after performing the experiment three times and summarized in Table 6.
  • Example 1 (10 ppm) 4.6 55.77
  • Example 1 (20 ppm) 2.7 74.04
  • Example 2 (10 ppm) 4.8 53.85
  • Example 2 (20 ppm) 4.1 60.58
  • Example 3 (10 ppm) 7.6 26.92
  • Example 3 (20 ppm) 4.5 56.73
  • Example 4 (10 ppm) 6.7 35.58
  • Example 4 (20 ppm) 5.2 50.00
  • Example 5 (20 ppm) 4.2 59.62
  • Example 6 (10 ppm) 7.1 31.73
  • Example 6 (20 ppm) 4.6 55.77
  • Example 7 (10 ppm) 5.1 50.96
  • Example 7 (20 ppm) 3.6 65.38
  • Human fibroblast cells human fibroblast cells
  • a 96-well plate 96 well plate, Corning
  • Examples 1 to 7 a concentration of 1% for 2 days
  • Cell proliferation was evaluated. More specifically, human fibroblasts were counted and distributed using a hemocytometer equal to 5 x 10 3 cells per well in a 24-well plate.
  • DMEM DMEM containing 10% FBS for 48 hours, and incubated for 40-50% of the surface area of the culture vessel, the sample was replaced with FBS-free DMEM and further cultured for 24 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition cosmétique, une composition alimentaire ou une composition quasi-médicamenteuse, comprenant, en tant que composants efficaces, des extraits d'acide gallique, de biancaea sappan, de rheum undulatum, d'euodia officinalis, de potentilla kleiniana, de graines de toona sinensis, ou de piper methysticum. Plus spécifiquement, lesdits extraits utilisés en tant que composants efficaces de la présente invention présentent les effets suivants : pouvoir antioxydants ; soulagement des troubles de la peau ; réduction des rides ; hydratation de la peau ; éclaircissement de la peau ; amélioration de l'élasticité de la peau ; et régénération de la peau. La composition de la présente invention est efficace en termes d'anti-saccharification, de réduction de la mélanine, d'anti-inflammation, de promotion de la synthèse du collagène, d'inhibition des activités de l'élastase et de prolifération cellulaire, et peut ainsi être avantageusement utilisée pour son pouvoir antioxydant, le soulagement des troubles de la peau, la réduction des rides, l'hydratation de la peau, l'éclaircissement de la peau, l'amélioration de l'élasticité de la peau et la régénération de la peau. Par conséquent, la composition de la présente invention peut être utilisée en tant que composition cosmétique, composition alimentaire, ou composition quasi-médicamenteuse sans danger pour la peau, fournissant des effets bénéfiques pour l'entretien de la peau.
PCT/KR2019/009888 2018-10-02 2019-08-07 Composition pour améliorer la peau comprenant des extraits de produits naturels WO2020071630A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180117818A KR102158780B1 (ko) 2018-10-02 2018-10-02 천연소재 추출물을 포함하는 피부 개선용 조성물
KR10-2018-0117818 2018-10-02

Publications (1)

Publication Number Publication Date
WO2020071630A1 true WO2020071630A1 (fr) 2020-04-09

Family

ID=70055282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/009888 WO2020071630A1 (fr) 2018-10-02 2019-08-07 Composition pour améliorer la peau comprenant des extraits de produits naturels

Country Status (2)

Country Link
KR (1) KR102158780B1 (fr)
WO (1) WO2020071630A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102589946B1 (ko) * 2021-01-25 2023-10-17 주식회사 셀아이콘랩 α-MSH 경쟁효과와 티로시나아제 저해효과를 동시에 가지는 신규의 멜라닌 색소 형성 억제용 화장료 조성물
KR102553924B1 (ko) 2021-01-26 2023-07-10 한국한의약진흥원 3-디옥시사파논 b를 유효성분으로 함유하는 항산화, 미백 및 항주름효과가 우수한 피부 개선용 화장료 조성물
KR20230103387A (ko) 2021-12-31 2023-07-07 대전대학교 산학협력단 섬애약쑥 추출물을 유효성분으로 함유하는 항산화, 항가려움 및 피부 미백용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010026175A (ko) * 1999-09-03 2001-04-06 서경배 천연식물 추출물을 함유하는 미백용 조성물
KR20040059007A (ko) * 2002-12-27 2004-07-05 주식회사 엘지생활건강 멜라닌 생성 억제 활성을 갖는 식물 추출물을 함유하는피부미백용 화장료
KR20070010216A (ko) * 2005-07-18 2007-01-24 주식회사 엘지생활건강 피부외용제 조성물
US20080175934A1 (en) * 2006-12-29 2008-07-24 Himalaya Global Holdings Limited Novel herbal composition of extracts of quercus infectoria, process for preparing the same and use thereof
KR20110094859A (ko) * 2010-02-18 2011-08-24 웅진코웨이주식회사 카바 추출물을 포함하는 콜라겐 합성 촉진용 조성물
KR20150000723A (ko) * 2013-06-25 2015-01-05 한국콜마주식회사 항균 활성을 갖는 가락지나물 추출물을 포함하는 화장료 조성물
KR20180089151A (ko) * 2017-01-31 2018-08-08 세명대학교 산학협력단 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물 및 피부보습제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4082823B2 (ja) 1999-05-06 2008-04-30 日本メナード化粧品株式会社 光毒性抑制剤
JP4250514B2 (ja) 2003-12-02 2009-04-08 一丸ファルコス株式会社 メラニン生成抑制剤
JP5236704B2 (ja) 2010-08-26 2013-07-17 一丸ファルコス株式会社 チロシナーゼ活性阻害剤
KR101952695B1 (ko) 2017-10-19 2019-02-27 주식회사 익스플즌 천연물질을 이용한 주름개선 화장료 조성물 및 이를 포함하는 화장품

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010026175A (ko) * 1999-09-03 2001-04-06 서경배 천연식물 추출물을 함유하는 미백용 조성물
KR20040059007A (ko) * 2002-12-27 2004-07-05 주식회사 엘지생활건강 멜라닌 생성 억제 활성을 갖는 식물 추출물을 함유하는피부미백용 화장료
KR20070010216A (ko) * 2005-07-18 2007-01-24 주식회사 엘지생활건강 피부외용제 조성물
US20080175934A1 (en) * 2006-12-29 2008-07-24 Himalaya Global Holdings Limited Novel herbal composition of extracts of quercus infectoria, process for preparing the same and use thereof
KR20110094859A (ko) * 2010-02-18 2011-08-24 웅진코웨이주식회사 카바 추출물을 포함하는 콜라겐 합성 촉진용 조성물
KR20150000723A (ko) * 2013-06-25 2015-01-05 한국콜마주식회사 항균 활성을 갖는 가락지나물 추출물을 포함하는 화장료 조성물
KR20180089151A (ko) * 2017-01-31 2018-08-08 세명대학교 산학협력단 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물 및 피부보습제

Also Published As

Publication number Publication date
KR20200038115A (ko) 2020-04-10
KR102158780B1 (ko) 2020-09-22

Similar Documents

Publication Publication Date Title
WO2019045259A2 (fr) Composition cosmétique comprenant un extrait de fleur de dendrobium candidum wallich ex lindley
WO2020071630A1 (fr) Composition pour améliorer la peau comprenant des extraits de produits naturels
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
WO2015156439A1 (fr) Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant
WO2019098468A1 (fr) Composition alimentaire ou cosmétique destinée au blanchiment de la peau, à l'hydratation de la peau ou à la diminution des rides de la peau, comprenant un composite de poudre de placenta de mouton et de plantes
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
WO2020076101A1 (fr) Composition de blanchiment de la peau anti-bactérienne ou anti-atopique contenant un extrait de syzygium formosum en tant que principe actif
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2017146414A1 (fr) Composition pour l'hydratation de la peau et atténuation des rides cutanées, contenant du α-terpinéol en tant que substance active
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
WO2013129723A1 (fr) Composition d'amélioration d'états de la peau comprenant de l'hordénine
WO2022085858A1 (fr) Composition pour le blanchiment de la peau ou l'amélioration des rides comprenant un extrait de dendropanax morbiferus
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2017142265A1 (fr) Composition contenant de l'acide adipique utilisé comme principe actif pour l'atténuation des rides de la peau et l'amélioration de l'élasticité de la peau
WO2017119535A1 (fr) Composition anti-âge comprenant de la carnosine, peptide de soja, et extrait d'andrographis paniculata
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2020032296A1 (fr) Composition fonctionnelle
WO2014003224A1 (fr) Compositions de blanchiment de la peau comprenant de la madécassoside
WO2014157910A1 (fr) Composition contenant un extrait de thanaka traité par une enzyme
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
KR20120081289A (ko) 아이소리퀴리티게닌 함량이 증가된 감초 발효물을 함유하는 피부외용제 조성물
KR102054132B1 (ko) 민물김 추출물을 유효성분으로 포함하는 피부 미백용 조성물
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
WO2017003190A1 (fr) Composition cosmétique éclaircissante comprenant un extrait de racine de caragana sinica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19869389

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20.08.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19869389

Country of ref document: EP

Kind code of ref document: A1